



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
Corporate Office : Cnergy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2018

Sl.No.	PART I - Particulars	Quarter ended			(Rs. in lakhs)
		30-06-2018	31-03-2018	30-06-2017	Year ended
		Unaudited	Refer note no. 7	Unaudited	Audited
1	Revenue from Operations	36,597.17	31,883.52	28,383.78	1,25,473.42
2	Other Income	111.72	1,109.46	927.18	3,525.53
3	Total Income (1+2)	36,708.89	32,992.98	29,310.96	1,28,998.95
4	Expenses				
	a. Cost of materials consumed	11,100.08	11,771.17	8,818.82	38,701.68
	b. Purchases of stock-in-trade	2,469.39	727.51	2,436.92	9,304.46
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(409.59)	(159.59)	(134.24)	(38.81)
	d. Employee benefit expenses	5,937.70	5,538.30	5,582.17	21,730.93
	e. Finance Costs	127.23	95.12	79.12	341.36
	f. Depreciation and amortization expense	1,446.52	1,304.30	1,432.84	5,594.85
	g. Other Expenses	10,089.44	10,036.19	8,573.34	35,460.18
	Total Expenses (4)	30,760.77	29,313.00	26,788.97	1,11,094.65
5	Profit before Tax (3-4)	5,948.12	3,679.98	2,521.99	17,904.30
6	Tax expenses	1,741.07	1,474.05	485.26	5,104.16
7	Net Profit/(Loss) after Tax (5-6)	4,207.05	2,205.93	2,036.73	12,800.14
8	Other Comprehensive Income (net of Tax)	(61.80)	(147.84)	(67.61)	(241.63)
9	Total Comprehensive Income after Tax (7+8)	4,145.25	2,058.09	1,969.12	12,558.51
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	5.03	2.63	2.32	15.24
	(2) Diluted	5.03	2.63	2.32	15.24

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 10, 2018.
- The auditors have carried out limited review of the financial results for the quarter ended on June 30, 2018 and their report does not contain any qualification.
- On July 6, 2018, one reactor at Company's API unit at Panoli, Gujarat exploded/caught fire that damaged surrounding civil structure and equipment. The buildings, plant, machinery and other assets at the said unit are fully covered by insurance. Out of the 8 plants at the unit catering to different products, plant & machinery/civil structure of 4 plants has been affected by the incident, while the manufacturing activity at the other plants is as usual. Commencement of commercial manufacturing at the affected plants is expected to take around 9 to 10 months. During financial year 2018-19, the Company foresees loss of sales to the tune of Rs. 5 crores and incur additional cost of about Rs. 2 crores on procurement of certain APIs from outside. The Company does not consider this impact as material keeping in view the size of its operations. The insurance claim amount is not yet crystalized as the loss assessment is yet to be over.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the quarter ended June 30, 2018 is not comparable with the previous corresponding quarter as the figures for the previous quarter was inclusive of excise duty.
- Effective April 1, 2018 the Company has adopted Ind AS 115 ' Revenue from contracts with customers'. Based on the assessment done by the management, there is no material impact on the revenue recognised during the quarter.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the quarter ended on March 31, 2018 are the balancing figures between audited figures in respect of the year ended on March 31, 2018 and published year-to-date figures up to December 31, 2017.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody
Chairman & Managing Director

Place : Mumbai
Date : 10/08/2018